Patent Law Weblog
Category: Licensing
-
By Sherri Oslick — On Wednesday, Amgen Inc. of Thousand Oaks, CA announced that it would acquire drug company Alantos Pharmaceuticals of Cambridge, MA for $300 million cash. Alantos is a private company developing small molecule drugs for diabetes and inflammatory diseases. Following acquisition, Alantos will be a wholly owned subsidiary of Amgen.…
-
By Jason Derry — GenomeQuest, Inc. has announced that ARYx Therapeutics has signed on to use its GenomeQuest search and analysis application. As previously discussed on Patent Docs, GenomeQuest is a bioinformatics company that provides web-enabled applications for genetic sequence searching and analysis. ARYx is a pharmaceutical research and development company that uses…
-
By Sherri Oslick — On Monday, Amgen Inc. of Thousand Oaks, CA announced that it would acquire drug company Ilypsa, Inc. of Santa Clara, CA for $420 million cash. Ilypsa, formerly Symyx Therapeutics, is a private company developing non-absorbed, GI based drugs for phosphate, potassium, and sodium management in patients with chronic kidney…
-
By Jason Derry — Novacea, Inc. and Schering-Plough have announced an agreement to develop and commercialize Asentar®, which is currently in Phase III clinical trials for the treatment of prostate cancer. Novacea is to receive an upfront payment of $60 million and $12 million in common stock. Novacea may also receive up to…
-
By Jason Derry — Siena Biotech S.p.A. has announced that it has entered a collaboration agreement with Roche relating to discovery and development of treatments for neurodegenerative diseases. Under the Agreement, Roche and Siena Biotech will engage in joint research activities involving screening and generating compounds, modeling and drug design, compound optimization, and…
-
By Christopher P. Singer — On May 7, 2007, Australian biotech companies EvoGenix Ltd. and Peptech Ltd. announced that they are planning a merger that would form one of Australia’s largest biotechnology companies. The new company, yet to be named, would continue to focus on antibody technology and protein therapeutics, in particular in…
-
By Jason Derry — Gene Logic Inc. announced today will collaborate with Abbott Laboratories to discover drug candidates that can be returned to clinical development. Gene Logic analyzes drug candidates that were once involved in clinical trials, but then were discontinued for reasons not related to safety. Abbott hopes that Gene Logic can…
-
By Kevin E. Noonan — The crisis regarding the pricing of patented drugs in poor and developing countries continues this week, with actions by current and former U.S. chief executives contributing to the situation. The U.S. Trade Representative issued a "Special 301 Report" on Monday, pursuant to the provisions of the Trade Act…
-
By Kevin E. Noonan — Treaties have a funny way of not having the results expected when they are signed. The Versailles Treaty and the Briand-Kellogg Pact did not prevent Germany from rearming prior to World War II; the United Nations Charter did not prevent the General Assembly from adopting resolutions contrary to…
-
By Kevin E. Noonan — There is a growing trend in developing countries (such as Brasil, China, India, and Thailand) for their governments to avail themselves of the ability under prevailing international trade agreements to grant compulsory licenses or permit so-called "parallel imports" of generic drugs in the face of national patents procured…
Patent Docs 